SAWAI GROUP HOLDINGS Co.,Ltd. Q4 FY2025 earnings call

Corporate Base & Governance Improvement

• Establishes "building a trusted corporate foundation" as its core priority, with four ongoing improvement initiatives led by a CEO-led corporate culture reform project
• Strengthens governance transparency, with clear accountability for the president, executive officers, and internal audit at the holding company board level
• Invests in raising on-site GMP/GQP capabilities, fostering a company-wide quality culture through compliance training and organizational reform, and improves alignment between manufacturing and sales divisions

Generic Pharmaceuticals Business Strategy

• Positions the current "Beyond 2027" mid-term management plan as a foundational period for the 2030 long-term vision, focused on preparing for future growth, portfolio restructuring, and investing in synergistic new areas
• Targets steady growth and long-term business sustainability in the generic drug market, with new product development and stable supply as key growth drivers
• Aims to raise utilization of completed production investments at Trust Pharmatech and the new Second Kyushu Plant wing, add 150 production employees in FY2024 and 271 employees (including 201 new graduates) in FY2025 to address labor shortages
• Plans to expand total in-house production capacity from 20.5 billion tablets to 22 billion tablets during the mid-term plan, and reach 25 billion tablets by FY2030 to prepare for industry consolidation

Growth Investment in New Business Areas

• Continues investment in high-growth adjacent healthcare areas, with non-invasive neuromodulation device Relivion and reduced drinking therapy support app HAUDY scheduled to launch in FY2025
• New digital/device businesses are structured to deliver stable revenue independent of Japanese drug price revisions, with synergy with the existing generic pharmaceutical business

Management Base Strengthening

• Identifies human capital investment as a top priority to address industry-wide labor shortages and support long-term growth
• Advances ESG initiatives including climate change action and ID&E (inclusion, diversity & equity), and transitioned to an audit and supervisory committee company in March 2025 to improve governance and speed up decision-making
• Achieved ROE/ROIC targets (excluding the impact of US business sale) in the first year of the mid-term plan, and allocates 1.9 trillion yen total (1.45 trillion yen from generic operating cash flow + 450 billion yen from asset sales) to priority growth investment in R&D and production capacity
• Commits to balancing growth and shareholder returns: maintains a target DOE of 3%+, approved a record high annual dividend of 53 yen per share for FY2024, and plans a 2 yen increase to 55 yen per share for FY2025

Segment-level financial breakdown is not provided in the available transcript. Aggregate consolidated results for FY2024 are: sales revenue increased 6.9% year-over-year, core operating profit increased 7.4% YoY, operating profit increased 11.7% YoY, and parent company attributable net profit grew significantly YoY driven by a gain on the sale of US business stake completed in April 2023. Core operating profit saw a 1.8 billion yen increase overall, while full operating profit increased 2.2 billion yen after accounting for gains on tangible asset sales.

• For FY2025 (March 2026 full year), management expects 5.9% YoY sales revenue growth, 8.9% YoY core operating profit growth, and 23% YoY operating profit growth. Parent company attributable net profit is expected to decline 24.1% YoY due to the absence of the prior year's US business stake sale gain
• Selling, general and administrative expenses are projected to increase 21.2% YoY driven by upfront investment in new businesses, while R&D expenses are expected to remain flat compared to FY2024 after excluding the 3 billion yen impairment recorded in the prior year
• All quantitative targets for the mid-term plan and 2030 long-term vision are maintained, with management confirming a firm commitment to achieving these goals
• Gross profit is projected to increase 7.6 billion yen in FY2025, supported by sales volume growth and product mix improvement from newly launched products

• The Japanese generic pharmaceutical industry is facing accelerating consolidation and淘汰 as drug price reforms require all firms to build stable supply capacity and quality assurance systems, creating increasing competitive pressure between market leaders and smaller players
• The company currently has 119 products under restricted or halted shipment, and resolving these limited shipments is dependent on production capacity expansion and broader industry supply conditions, with no clear timeline for full resolution
• Development of higher-cost, higher-complexity products has increased the risk of impairment charges for pre-launch development assets when market conditions change from initial projections
• New product sales missed FY2024 targets, creating a 20 billion yen gap against mid-term plan sales targets that management must close in subsequent years
• Industry-wide labor shortages create ongoing pressure for higher labor costs and can delay production capacity expansion

Q: Why were valuation losses, disposal losses, and impairment losses higher than usual in FY2024, and will this elevated level continue? / A: Most impairment came from pre-launch development assets, which are evaluated annually with conservative assumptions around authorized generic competition, market size, and profitability. Longer development timelines and rising development costs have increased the chance of projects falling short of initial projections. The company will increase impairment testing frequency from annual to improve visibility and update development feasibility screening to be more realistic. Disposal losses came from canceled development project inventory and expired stock, plus stricter handling of non-conforming product. Losses will not reach FY2024 levels going forward, though some level will always be budgeted.

Q: What is Sawai's investment strategy for new business areas, and what is the path to profitability for digital healthcare initiatives? / A: Investment focuses on adjacent healthcare areas that leverage synergies with the existing pharmaceutical business and deliver stable revenue unimpacted by Japanese drug price revisions. Digital products like the PHR app SaluDi already receive strong physician interest and support existing sales activities by adding value for clinical providers. The HAUDY reduced drinking app and Relivion neuromodulation device target underserved patient populations that do not respond well to traditional pharmaceuticals, creating an untapped blue ocean market. Management expects the new businesses to contribute material revenue within the current mid-term plan, with an explicit priority on reaching profitability as quickly as possible, and upfront investment is budgeted to build market share before competitors enter.

Q: What is the path to hitting mid-term plan targets after a lower-than-expected first year, especially for core operating profit? / A: The current mid-term plan sales target is 20 billion yen behind plan, which management has made a top priority to close in FY2025. A new monthly executive steering committee led by the CEO has been formed to prioritize production allocation by business value, align sales demand with output, and adjust the product portfolio to market needs. The 5.5 billion yen gap to the 33 billion yen core operating profit target for the plan is achievable through a combination of profit margin improvements and targeted pricing actions, and management is fully committed to hitting the final target. The 2026 industry corporate rating reform is a key inflection point that will create large market share shifts between high-rated and low-rated firms, and Sawai is preparing its operations to capture this growth opportunity.

Q: Why is the sales volume forecast conservative even as production capacity grows 10% in FY2025? / A: The sales forecast was built conservatively by individually reviewing the top 200 products, with stable demand from the selected therapy system already priced in. Production is being increased to build safety stock for products that have not yet reached stable inventory levels, which is required to lift restricted shipment status. The company is also building inventory ahead of planned new product launches in late FY2025, which will contribute more significantly to sales in FY2026. A strong 9 billion yen contribution is already budgeted from growth of FY2024-launched new products, but uncertainty around competitor entry for FY2025 new launches makes final forecasting difficult at this stage.